- Home
- KYMR vs GDRX Comparison
KYMR vs GDRX Comparison
Compare KYMR & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- GDRX
- Stock Information
- Founded
- KYMR 2015
- GDRX 2011
- Country
- KYMR United States
- GDRX United States
- Employees
- KYMR N/A
- GDRX N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- GDRX Retail: Computer Software & Peripheral Equipment
- Sector
- KYMR Health Care
- GDRX Technology
- Exchange
- KYMR Nasdaq
- GDRX Nasdaq
- Market Cap
- KYMR 2.2B
- GDRX N/A
- IPO Year
- KYMR 2020
- GDRX 2020
- Fundamental
- Price
- KYMR $29.62
- GDRX $4.50
- Analyst Decision
- KYMR Buy
- GDRX Buy
- Analyst Count
- KYMR 13
- GDRX 10
- Target Price
- KYMR $56.69
- GDRX $8.68
- AVG Volume (30 Days)
- KYMR 591.0K
- GDRX 1.7M
- Earning Date
- KYMR 05-01-2025
- GDRX 05-08-2025
- Dividend Yield
- KYMR N/A
- GDRX N/A
- EPS Growth
- KYMR N/A
- GDRX N/A
- EPS
- KYMR N/A
- GDRX 0.04
- Revenue
- KYMR $47,072,000.00
- GDRX $792,324,000.00
- Revenue This Year
- KYMR $44.93
- GDRX $6.14
- Revenue Next Year
- KYMR N/A
- GDRX $6.58
- P/E Ratio
- KYMR N/A
- GDRX $112.50
- Revenue Growth
- KYMR N/A
- GDRX 5.61
- 52 Week Low
- KYMR $29.07
- GDRX $4.09
- 52 Week High
- KYMR $53.27
- GDRX $9.26
- Technical
- Relative Strength Index (RSI)
- KYMR 33.94
- GDRX 43.51
- Support Level
- KYMR $29.83
- GDRX $4.31
- Resistance Level
- KYMR $35.28
- GDRX $4.95
- Average True Range (ATR)
- KYMR 1.79
- GDRX 0.22
- MACD
- KYMR -0.20
- GDRX -0.00
- Stochastic Oscillator
- KYMR 4.54
- GDRX 29.92
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.